May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Topical Moxifloxacin Prevents Endophthalmitis After Triamcinolone Intravitreal Injection in a Rabbit Model
Author Affiliations & Notes
  • R. P. Kowalski
    Ophthalmology/Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • E. G. Romanowski
    Ophthalmology/Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • F. S. Mah
    Ophthalmology/Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • K. A. Yates
    Ophthalmology/Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Y. J. Gordon
    Ophthalmology/Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Footnotes
    Commercial Relationships R.P. Kowalski, Alcon, F; Alcon, C; E.G. Romanowski, Alcon, F; Alcon, C; F.S. Mah, Alcon, F; Alcon, C; Alcon, R; K.A. Yates, None; Y.J. Gordon, Alcon, F; Alcon, C.
  • Footnotes
    Support Alcon Laboratories, Ft. Worth, TX
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2674. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. P. Kowalski, E. G. Romanowski, F. S. Mah, K. A. Yates, Y. J. Gordon; Topical Moxifloxacin Prevents Endophthalmitis After Triamcinolone Intravitreal Injection in a Rabbit Model. Invest. Ophthalmol. Vis. Sci. 2007;48(13):2674.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Frequent intravitreal injections of triamcinolone for the treatment of macular disease has increased the chance of endophthalmitis. In this in vivo study, we investigated the potential of topical moxifloxacin (Vigamox) to prevent endophthalmitis after an intravitreal injection of triamcinolone.

Methods:: A rabbit model of intravitreal injection was developed by injecting triamcinolone into the vitreal cavity through a depot of subconjunctival Staphylococcus aureus (107 colony forming units) that was deposited 1 hour earlier. Endophthalmitis was determined by typical clinical presentations and confirmation by a positive bacterial culture from the vitreous. The model was tested with two topical treatment groups: 1) 10 Vigamox and 2) 10 saline. In brief, after S. aureus subconjunctival challenge, topical treatment was administered every 15 minutes for 1 hour (5 drops) immediately before an intravitreal injection of triamcinolone (4 mg/0.1 ml) through the treated bacterial depot. Topical Vigamox or saline was administered QID over the next 72 hours. All rabbits were examined daily, sacrificed, and tested for viable bacteria when clinical signs of endophthalmitis were observed. Remaining animals were sacrificed and tested for viable bacteria at 72 hours.

Results:: Antibiotic treatment with topical Vigamox (0/9) prevented the development of endophthalmitis in comparison with topical saline (6/10) (Fisher’s exact, p=0.01). The Vigamox treated eyes were culture-negative compared to the median colony count of 1.55 x 105 cfu/ml for the saline treated. (Mann-Whitney, p=0.02) The total clinical scores for the saline treated eyes (17.17) were significantly higher than the Vigamox treated (1.28). (p=0.0001, ANOVA)

Conclusions:: Topical Vigamox prevented endophthalmitis after an intravitreal injection of triamcinolone. The clinical implication is that Vigamox may prevent endophthalmitis after intravitreal injection by eliminating the bacteria flora at the injection site. Additional clinical studies are needed to support this implication.

Keywords: antibiotics/antifungals/antiparasitics • endophthalmitis • Staphylococcus 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×